Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 18/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 18/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 16/20 | 0.49 |
| ▸ | MTOR | P42345 | 6/20 | 0.49 |
| ▸ | PIK3C3 | Q8NEB9 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12078765 | 0.89 | KCNH2 (0.59) | KCNH2MAPK1PIK3CDPIK3CGPIK3CB | |
| SCHEMBL18123071 | 0.88 | MAPK1 (0.51) | KCNH2MAPK1PIK3CDPIK3CGPIK3CB | |
| SCHEMBL12495977 | 0.86 | MAPK1 (0.53) | KCNH2MAPK1PIK3CDPIK3CGPIK3CB | |
| SCHEMBL18112912 | 0.85 | MAPK1 (0.52) | KCNH2MAPK1PIK3CDPIK3CGPIK3CB | |
| SCHEMBL12495639 | 0.85 | KCNH2 (0.55) | KCNH2MAPK1PIK3CDPIK3CGPIK3CB | |
| SCHEMBL18113043 | 0.84 | MAPK1 (0.49) | KCNH2MAPK1 | |
| SCHEMBL12495999 | 0.84 | KCNH2 (0.57) | KCNH2MAPK1PIK3CDPIK3CGPIK3CB | |
| SCHEMBL18113024 | 0.83 | MAPK1 (0.54) | KCNH2MAPK1 | |
| SCHEMBL18112896 | 0.82 | MAPK1 (0.47) | KCNH2MAPK1 | |
| SCHEMBL12496057 | 0.81 | MAPK1 (0.51) | KCNH2MAPK1PIK3CDPIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016161145-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-06 | — | — | WO | claimed |
| US-10710978-B2 | STK4 inhibitors for treatment of hematologic malignancies | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2018-04-26 | — | — | US | disclosed |
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2018-04-26 | — | — | US | disclosed |
| WO-2016161145-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161145-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | STK4, STK3, STK11 | KCNH2 2512/4885MAPK1 341/4885PIK3CD 428/4885 |
| US-10710978-B2 | STK4 inhibitors for treatment of hematologic malignancies | STK4, STK3, STK11 | KCNH2 2512/4885MAPK1 341/4885PIK3CD 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.